Dana Piovesan, Amber E de Groot, Soonweng Cho, Amy E Anderson, Rebecca D Ray, Amita Patnaik, Paul G Foster, Casey G Mitchell, Alejandra Y Lopez Espinoza, Wandi S Zhu, Carlo E Stagnaro, Hema Singh, Xiaoning Zhao, Lisa Seitz, Nigel P Walker, Matthew J Walters, Kelsey E Sivick
TIGIT is an inhibitory receptor on immune cells that outcompetes an activating receptor, CD226, for shared ligands. Tumor-infiltrating lymphocytes express TIGIT and CD226 on regulatory T cells (Treg) and on CD8+ T cells with tumor-reactive or exhausted phenotypes, supporting the potential of therapeutically targeting TIGIT to enhance anti-tumor immunity. To optimize the efficacy of therapeutic antibodies against TIGIT, it is necessary to understand whether there is therapeutic benefit from Fcγ receptor (FcγR) binding...
April 18, 2024: Cancer Research